Chronic obstructive pulmonary disease Management and Follow up.

1.    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report.

2.    Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, Criner GJ, et al: . Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 May 1;201(9):e56-e69.

3.    Wang Z, Lin J, Liang L, Huang F, Zheng J. Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021. Respir Res. 2025 Jan 2;26(1):2.

4.  World Health Organization, Chronic obstructive pulmonary disease (COPD). fact sheet. WHO, Geneva (2025) [citedSept 04].Available from  https://www.who.int/news-room/factsheets/detail/chronic-obstructive-pulmonary-disease-(copd)

5.    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report : GOLD; 2023.

6.    Wang Z, Qiu Y, Ji X, Dong L. Effects of smoking cessation on individuals with COPD: a systematic review and meta-analysis. Front Public Health. 2024 Dec 11; 12:1433269. doi: 10.3389/fpubh.2024.1433269. PMID: 39722704; PMCID: PMC11668769.

7.    Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, Montes de Oca M, Papi A, Sin DD, Han MK, Agusti A. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. Am J Respir Crit Care Med. 2022 Dec 1;206(11):1317-1325.

8.    Sugawara H, Saito A, Yokoyama S, Tsunematsu K, Chiba H. Association between annual change in FEV1 and comorbidities or impulse oscillometry in chronic obstructive pulmonary disease. BMC Pulm Med. 2022 May 8;22(1):185.

9.    Miravitlles, M., Ribera, A. Understanding the impact of symptoms on the burden of COPD. Respir Res 18, 67 (2017).

10.    KARLOH, M., FLEIG MAYER, A., MAURICI, R., PIZZICHINI, M. M., JONES, P. W. & PIZZICHINI, E. 2016. The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages. Chest, 149, 413-25.

11.    Singh D, Stockley R, Anzueto A, Agusti A, Bourbeau J, Celli BR, Halpin D. et al, GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD. Eur Respir J. 2025 Feb 6;65(2):2401603.

12.  Rossi A, Butorac-Petanjek B, Chilosi M, et al. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies. Int J Chron Obstruct Pulmon Dis. 2017 Aug 29; 12:2593-2610.

13.  Couper D,LaVange LM,Han M,et al. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax. 2014;69(5):492-495. 

14.   Tsiligianni, I.G., van der Molen, T., Moraitaki, D. et al. Assessing health status in COPD. Head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med 12, 20 (2012).

15.   Checkley W, Yang M, Robertson NM, Sharma AK, Chandyo RK, Shrestha L, Das SK, Kirenga B, Alupo P, Gianella G, Siddharthan T, Pollard SL, Quaderi S, Rykiel N, Flores-Flores O, Hurst JR, Wise RA; Global Excellence in COPD outcomes (GECo) Study Investigators. Population-Based Screening for Chronic Obstructive Pulmonary Disease Using the St. George's Respiratory Questionnaire in Resource-Limited Settings. Am J Respir Crit Care Med. 2025 May;211(5):779-788.

16.  Peng J, Wang M, Wu Y, Shen Y, Chen L. Clinical Indicators for Asthma-COPD Overlap: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2022 Oct 12;17:2567-2575.

17. Shifren A, Witt C, Christie C, Castro M. Mechanisms of remodeling in asthmatic airways. J Allergy (Cairo). 2012;2012:316049.

18.   Vogelmeier CF, Friedrich FW, Timpel P, Kossack N, Diesing J, Pignot M, Abram M, Gediga M, Halbach M. Comorbidities and Cause of Death in COPD Patients Compared to Non-COPD Controls: An 8-year Observational Retrospective Healthcare Claims Database Cohort Study. Int J Chron Obstruct Pulmon Dis. 2025 Jun 27;20:2117-2130.

19.   Recio Iglesias J, Díez-Manglano J, López García F, Díaz Peromingo JA, Almagro P, Varela Aguilar JM. Management of the COPD Patient with Comorbidities: An Experts Recommendation Document. Int J Chron Obstruct Pulmon Dis. 2020 May 7;15:1015-1037.

20.   National Asthma & COPD Guidelines, ministry of health in collaboration with Egyptian society of chest diseases and tuberculosis Egypt , 2023

21.  Hurst JR, Han MK, Singh B, Sharma S, Kaur G, de Nigris E, Holmgren U, Siddiqui MK. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022 Aug 23;23(1):213.

22.  Miravitlles, M., Kostikas, K., Bizymi, N. & Tzanakis, N. A Novel Figure and Algorithm for the gold ABE Classification 702–704 (Elsevier, 2023).

23.   Halpin DMG, Healey H, Skinner D, Carter V, Pullen R, Price D. Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations. Eur Respir J. 2024 Oct 3;64(4):2302240.

24.  Van Dijk M, Gan CT, Koster TD, Wijkstra PJ, Slebos DJ, Kerstjens HAM, van der Vaart H, Duiverman ML. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Res. 2020 Sep 21;6(3):00322-2019.

25.   Kumar A, Kant S, Niranjan V. Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease. Cureus. 2024 May 16;16(5):e60423.

26.  Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk PD, van der Palen J, Effing TW. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. Randomised controlled trials (RCTs)

27.   López-Campos JL, Carrasco Hernández L, Ruiz-Duque B, Reinoso-Arija R, Caballero-Eraso C. Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies. Int J Chron Obstruct Pulmon Dis. 2021 Jul 12;16:2065-2076.

28.   Celli B, Vestbo J. Simplifying pharmacotherapy for patients with COPD: a viewpoint. Eur Respir J. 2023 Aug 17;62(2):2300115.

29.  Harries, T.H., Rowland, V., Corrigan, C.J. et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res 21, 3 (2020).

30. Singh D. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. Tuberc Respir Dis (Seoul). 2020 Jul;83(3):185-194. doi: 10.4046/trd.2020.0026. Epub 2020 Apr 29.

31.  Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al.  Once daily umeclidinium/vilanterol 125/25 mcg in COPD: randomized, controlled study. Chest 2014; 145:981–991.

32.   Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med  2014;2:472–486.

33. Lipson, D.A.; Criner, G.; Dransfield, M.; Halpin, D.; Han, M.; Jones, C.E.; Kilbride, S.; Lange, P.; Lomas, D.; Martinez, F.; et al. The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time. Eur. Respir. J. 2019, 54, PA2482.

34.  Martinez, F.J.; Rabe, K.F.; Ferguson, G.T.; Wedzicha, J.A.; Singh, D.; Wang, C.; Rossman, K.; Rose, E.S.; Trivedi, R.; Ballal, S.; et al. Reduced All-Cause Mortality in ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am. J. Respir. Crit. Care Med. 2021, 203, 553–564

35.   Li Y, Li J, Yang H, Zhang Y. Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2025 Jul 19;25(1):345.

36.   Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med  2016;4:390–398.

37.  Jenkins CR, Jones PW, Calverley PM, et al: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009 Jun 30;10(1):59.

38.    Vestbo J,Anderson JA,Brook RD,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-1826.

39.   Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res 2019; 20(1): 238

40.  Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using new GOLD classification: a study of general population. Am J Respir Crit Care Med 2012; 186(10): 975-81

41. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42(3): 636-46 .

42.  Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev 2018; 12(12): CD012620

43.  . Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018; 378(18): 1671-80

44.   Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med 2020; 383(1): 35-48 https

45.   Sanchis J, Gich I, Pedersen S; Aerosol Drug Management Improvement Team (ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest. 2016 Aug;150(2):394-406.

46. David M. G. Halpin, Donald A. Mahler, A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease, Annals of the American Thoracic Society, Volume 19, Issue 7, July 2022, Pages 1213–1220,

47.  Nakamura, K.; Fujita, Y.; Chen, H.; Somekawa, K.; Kashizaki, F.; Koizumi, H.; Takahashi, K.; et al: The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis. Diseases 2023, 11, 152.

48.  Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med 2024; 390(24): 2274-83

49.  Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF et al ; BOREAS Investigators. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20;389(3):205-214.

50.   Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D,et al: GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019 Sep 12;381(11):1023-1034.

51.  Lu HY, Chen CF, Lee DL, Tsai YJ, Lin PC. Effects of Early Pulmonary Rehabilitation on Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2023 May 15; 18:881-893.

52.   Vatrella A, Maglio A, Di Palo MP, Contursi EA, Buscetto AF, Cafà N, Garofano M, Del Sorbo R, Bramanti P, Pessolano C, Marino A, Calabrese M, Bramanti A. Effects of Pulmonary Rehabilitation on Dyspnea, Quality of Life and Cognitive Function in COPD: A Systematic Review. J Clin Med. 2026 Jan 14;15(2):670.

53. Díaz-Miravalls J, Romero-Linares A, Jiménez-Gómez M, Catalinas-Muñoz E, et al. Efficacy and Safety of Bronchoscopic Lung Volume Reduction With Endobronchial Valves: A Systematic Review and Meta-analysis. Open Respir Arch. 2025 May 17;7(3):100443.

54.  Hartman JE, Welling JB, Klooster K, Carpaij OA, Augustijn SW, Slebos D. Survival in COPD patients treated with bronchoscopic lung volume reduction. Respir Med. (2022) 196:106825. 10.1016/j.rmed.2022.106825

55.   Kwok WC, Wong JC, Cheung A, Tam TC. Vaccination in Chronic Obstructive Pulmonary Disease. Vaccines (Basel). 2025 Feb 22;13(3):218. 

56.   Bekkat-Berkani R., Wilkinson T., Buchy P., Dos Santos G., Stefanidis D., Devaster J.-M., Meyer N. Seasonal influenza vaccination in patients with COPD: A systematic literature review. BMC Pulm. Med. 2017;17:79.

57.  Khor YH, Palm A, Wong AW, et al Effects of long-term oxygen therapy on acute exacerbation and hospital burden: the national DISCOVERY study Thorax Published Online First: 20 March 2025. 

58. Katsenos S, Constantopoulos SH. Long-Term Oxygen Therapy in COPD: Factors Affecting and Ways of Improving Patient Compliance. Pulm Med. 2011; 2011:325362.

59.  Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD001744.

60.   Han T, Huang Q, Zhai Z, Zhang X. Nocturnal hypoxemia is associated with poor pulmonary hemodynamics in patients with chronic thromboembolic pulmonary disease. Respir Res. 2025 Jul 10;26(1):239.

61.    Macrea M, Oczkowski S, Rochwerg B, Branson RD, Celli B, Coleman JM 3rd, Hess DR, et al. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Aug 15;202(4):e74-e87.

62.  Ergan B, Oczkowski S, Rochwerg B, Carlucci A, Chatwin M, Clini E, Elliott M. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3):1901003.

63.  Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk PD, van der Palen J, Effing TW. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990.

64.   Bos-Touwen I, Jonkman N, Westland H, Schuurmans M, Rutten F, de Wit N, Trappenburg J. Tailoring of self-management interventions in patients with heart failure. Curr Heart Fail Rep. 2015 Jun;12(3):223-35.

65.   Effing TW, Vercoulen JH, Bourbeau J, Trappenburg J, Lenferink A, Cafarella P. Definition of a COPD self-management intervention: international expert group consensus. European Respiratory Journal 2016; 48:46-54